Shu Peng, Wu Jianping, Tong Yao, Xu Chunxia, Zhang Xingguo
Beilun People's Hospital, Ningbo.
Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Medicine (Baltimore). 2018 Oct;97(42):e12788. doi: 10.1097/MD.0000000000012788.
The identification of high-risk colorectal cancer (CRC) patient is key to individualized treatment after surgery and reliable prognostic biomarkers are needed identifying high-risk CRC patients.
We developed a gene pair based prognostic signature that could can the prognosis risk in patients with CRC. This study retrospectively analyzed 4 public CRC datasets, and 1123 patients with CRC were divided into a training cohort (n = 300) and 3 independent validation cohorts (n = 507, 226, and 90 patients).
A signature of 9 prognosis-related gene pairs (PRGPs) consisting of 17 unique genes was constructed. Then, a PRGP index (PRGPI) was constructed and divided patients into high- and low-risk groups according to the signature score. Patients in the high-risk group showed a poorer relapse-free survival than the low-risk group in both the training cohort [hazard ratio (HR) range, 4.6, 95% confidence interval (95% CI), 2.55-8.32; P < .0001] and meta-validation set (hazard ratio range, 4.09, 95% CI, 1.99-8.39; P < .0001). The PRGPI signature achieved a higher accuracy [mean concordance index (C-index): 0.6∼0.74] than a commercialized molecular signature (mean C-index, 0.48∼0.56) for estimation of relapse-free survival in comparable validation sets.
The gene pair based prognostic signature is a promising biomarker for estimating relapse-free survival of CRC.
识别高危结直肠癌（CRC）患者是术后个体化治疗的关键，需要可靠的预后生物标志物来识别高危CRC患者。
我们开发了一种基于基因对的预后特征，可对CRC患者的预后风险进行评估。本研究回顾性分析了4个公开的CRC数据集，将1123例CRC患者分为训练队列（n = 300）和3个独立验证队列（n = 507、226和90例患者）。
构建了一个由17个独特基因组成的包含9个预后相关基因对（PRGP）的特征。然后，构建了PRGP指数（PRGPI），并根据特征评分将患者分为高风险和低风险组。在训练队列[风险比（HR）范围为4.6，95%置信区间（95%CI）为2.55 - 8.32；P <.0001]和荟萃验证集（风险比范围为4.09，95%CI为1.99 - 8.39；P <.0001）中，高风险组患者的无复发生存期均比低风险组差。在可比的验证集中，PRGPI特征在估计无复发生存期方面比商业化分子特征（平均一致性指数（C指数）为0.48 - 0.56）具有更高的准确性[平均C指数为0.6 - 0.74]。
基于基因对的预后特征是评估CRC无复发生存期的有前景的生物标志物。
